SS
TGTX icon

SBI Securities’s TG Therapeutics TGTX Stock Holding History

SBI Securities’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Sell
400
-346
-46% -$14.2K ﹤0.01% 1512
2026
Q1 		$24.8K Sell
746
-17
-2% -$507 ﹤0.01% 1374
2025
Q4 		$22.7K Sell
763
-1,022
-57% -$33.4K ﹤0.01% 1388
2025
Q3 		$64.5K Sell
1,785
-600
-25% -$19.8K ﹤0.01% 993
2025
Q2 		$85.8K Buy
2,385
+1,789
+300% +$66.6K ﹤0.01% 872
2025
Q1 		$23.5K Sell
596
-112
-16% -$3.77K ﹤0.01% 1264
2024
Q4 		$21.3K Buy
+708
New +$20.3K ﹤0.01% 1324

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SBI Securities's TGTX Position: Q2 2026 in Review

SBI Securities reduced its TG Therapeutics (TGTX) stake by 46% in Q2 2026, selling an estimated $14.2K and leaving 400 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

SBI Securities first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $85.8K in Q2 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • SBI Securities held 400 shares of TG Therapeutics worth $22K as of Q2 2026.
  • SBI Securities sold 346 TG Therapeutics shares in Q2 2026, an estimated $14.2K.
  • TG Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1512 holding.
  • SBI Securities first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's TG Therapeutics position peaked at $85.8K in Q2 2025.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.